DIGENE CORP
10-K405, EX-27, 2000-09-28
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: DIGENE CORP, 10-K405, EX-23.1, 2000-09-28
Next: DIGENE CORP, DEF 14A, 2000-09-28



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-2000
<PERIOD-START>                             JUL-01-1999
<PERIOD-END>                               JUN-30-2000
<CASH>                                       7,534,998
<SECURITIES>                                12,678,819
<RECEIVABLES>                                5,050,578
<ALLOWANCES>                                   263,300
<INVENTORY>                                  4,400,297
<CURRENT-ASSETS>                            30,549,269
<PP&E>                                       6,971,470
<DEPRECIATION>                               3,393,382
<TOTAL-ASSETS>                              35,784,966
<CURRENT-LIABILITIES>                        6,281,342
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       161,735
<OTHER-SE>                                  29,263,133
<TOTAL-LIABILITY-AND-EQUITY>                35,784,966
<SALES>                                     22,287,483
<TOTAL-REVENUES>                            23,043,970
<CGS>                                        7,641,304
<TOTAL-COSTS>                               13,764,331
<OTHER-EXPENSES>                             (513,322)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 320
<INCOME-PRETAX>                            (6,582,838)
<INCOME-TAX>                                   184,368
<INCOME-CONTINUING>                        (6,767,206)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (6,767,206)
<EPS-BASIC>                                     (0.44)
<EPS-DILUTED>                                   (0.44)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission